Clinical Trials Logo

Clinical Trial Summary

To evaluate changes in genomic alterations for 73 PC driver genes during apalutamide treatment


Clinical Trial Description

This clinical study is an open-label, multicenter, interventional, Phase 4 study to evaluate changes in genomic alterations for 73 PC driver genes during apalutamide treatment in patients with mCSPC. A total of 100 participants to be treated by apalutamide will be registered in this study. All participants will undergo blood collection for ctDNA, single-nucleotide polymorphisms (SNPs), and human-leukocyte antigen (HLA) typing at pre- and posttreatment of apalutamide. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT04601441
Study type Interventional
Source Kindai University
Contact Hiroshi Yoshida
Phone +81-3-3830-1074
Email ctDNA@a2healthcare.com
Status Recruiting
Phase Phase 4
Start date November 6, 2020
Completion date March 31, 2025

See also
  Status Clinical Trial Phase
Active, not recruiting NCT04497844 - A Study of Niraparib in Combination With Abiraterone Acetate and Prednisone Versus Abiraterone Acetate and Prednisone for the Treatment of Participants With Deleterious Germline or Somatic Homologous Recombination Repair (HRR) Gene-Mutated Metastatic Castration-Sensitive Prostate Cancer (mCSPC) Phase 3
Recruiting NCT06120491 - Saruparib (AZD5305) vs Placebo in Men With Metastatic Castration-Sensitive Prostate Cancer Receiving Physician's Choice New Hormonal Agents Phase 3
Completed NCT04887506 - TAVT-45 (Abiraterone Acetate) Granules in Patients With Prostate Cancer Phase 3
Completed NCT05149131 - A Study Called AWARENESS Using Data From Men in Alberta to Observe Treatment Patterns for Metastatic Castration-sensitive Prostate Cancer
Active, not recruiting NCT04666129 - Study of Relugolix in Men With Metastatic Castration-Sensitive Prostate Cancer or Non-Metastatic or Metastatic Castration-Resistant Prostate Cancer Phase 1